Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 sept. 2019 07h00 HE | Source: Imvax, Inc.

Imvax Appoints John P. Furey as Chief Executive Officer

PHILADELPHIA, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Imvax, Inc., a discovery and clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy...
31 mars 2019 15h00 HE | Source: Imvax, Inc.

Imvax Announces Positive Results from Clinical Trial of Novel IGV-001 Autologous Cell Vaccine in Treating Patients with Newly Diagnosed Glioblastoma

Median overall survival was 21.9 months for highest vaccine dose vs. 14.6 months in published standard of care studies Median progression-free survival was 10.4 months vs. 6.9 and 5.4 months in...
27 mars 2019 08h00 HE | Source: Imvax, Inc.

Imvax to Present Results from Phase 1b Clinical Trial of IGV-001 in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2019

PHILADELPHIA, March 27, 2019 (GLOBE NEWSWIRE) -- Imvax, Inc., a clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies,...